ISLHD HAEMATOLOGY CLINICAL TRIALS

Illawarra Cancer Care Centre

May 2024

ISLHD CANCER CLINICAL TRIALS UNIT

Illawarra Cancer Care Centre Wollongong Hospital Loftus Street Wollongong NSW 2500

Ph: 02 4253 4384 Fax: 02 4222 5085 Email: ISLHD-CancerClinicalTrials@health. nsw.gov.au

Clinical Trials available through the Illawarra Shoalhaven Local Health District can be found on the ClinTrial Refer App. Scan the QR code below to download ClinTrial Refer.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.


Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Multiple Myeloma
- Acute myeloid Leukaemia

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Haematology Trials Clinician, please phone Haematology on 02 4253 4009



ISLHD Haematology Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

Scan the QR Code for more information including eligibility criteria

Multiple Myeloma

CA057-001: A Phase 3, Two-Stage, Randomized, Mul-Dr Parmar ticenter, Open-Label Study Comparing CC-92480, Kiara Porter/ Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM). **recruitment paused**

MonumenTAL-2: A multi-arm phase 1b study of

pants with multiple myeloma.

Recruitment paused

talquetamab with other anticancer therapies in partici-

Tegan Cutter *Satellite site



Dr Parmar Tegan Cutter/ Kiara Porter



MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide. Bortezomib. and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide.

TCD17710: First-in-human, open-label Phase 1/2 study Dr Parmar to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light chain amyloidosis (RRLCA). **Recruitment paused**

LTS17704: International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximabbased Therapy Following Completion of a Phase 1, 2, or 3 Parental Study. **Parental study TCD15484**

Dr Parmar Tegan Cutter/ Carla Brown



Felicity Carroll-Cross/ Cassandra Jory



Dr Parmar Tiffany Koutsouradis/ Amelia Feneck




Acute Leukaemia

AMLM22/D2: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.

Dr Presgrave Carla Brown





ISLHD Haematology Clinical Trials **CURRENTLY OPEN FOR RECRUITMENT**

For further information regarding these trials at the Illawarra Cancer Care Centre you may also contact the dedicated trial coordinator as listed or email <u>ISLHD-HaematologyTrials</u> @health.nsw.gov.au

Trial Coordinator	Availability	Contact details
Danielle Di Pietro (team leader)	Mon-Fri	02 4255 1415
Felicity Carroll-Cross	Mon-Fri	02 4253 4039
Tegan Cutter	Mon-Fri	02 4222 5553
Kiara Porter	Mon-Fri	02 4222 5276
Carla Brown	Mon-Wed	02 4253 4082
Cassandra Jory	Wed-Fri	02 4222 5227
Tiffany Koutsouradis	Wed-Fri	02 4253 4082
Jillian Dubose	Tues-Fri	02 4255 1495
Amelia Feneck	Mon-Wed	02 4222 5230

